17 Oct 2024
ZyVersa Therapeutics CEO, Stephen C. Glo ...
Lead indication for ZyVersa’s Inflammasome ASC Inhibitor IC 100 is obesity with metabolic complications. WESTON, Fla., Oct. 17, ...
Get access to the latest news, guides, stock and crypto updates, and take your financial portfolio to the next level.